摘要
目的探讨血清微小RNA(microRNA)预测乳腺癌早期生物学行为的可行性和临床应用价值。方法选取天津医科大学附属肿瘤医院2011年3—10月经病理诊断明确的乳腺癌患者165例为乳腺癌组,另选取我院体检的健康女性120例为对照组,采用实时定量聚合酶链反应(real-time PCR)测定血清microRNA相对表达量,采用t检验比较乳腺癌组与对照组血清中microRNA的差异,Mann Whitney检验和Kruskal Wallis检验比较microRNA相对表达量与乳腺癌临床病理特征的关系。结果乳腺癌组织microRNA差异表达谱共筛选4种表达差异明显的microRNA:miR-10b、miR-100、miR-155及miR-206。乳腺癌组较对照组miR-100、miR-206相对表达量下降,miR-155相对表达量升高,差异均有统计学意义(P<0.05);两组miR-10b相对表达量比较,差异无统计学意义(P>0.05)。乳腺癌淋巴结转移阳性与阴性患者miR-10b相对表达量,不同临床分期、突变型P53阳性与阴性、Ki-67<14%与≥14%患者miR-155相对表达量和不同分子分型、雌激素受体阳性与阴性患者miR-206相对表达量比较,差异均有统计学意义(P<0.05)。结论血清microRNA可以作为乳腺癌新的生物学标志物,其中血清miR-10b和miR-206可以分别用来早期预测乳腺癌患者淋巴结转移状态和雌激素受体状态,miR-155可以早期判断乳腺癌细胞的恶性程度、预测临床分期。
Objective To explore the feasibility and value of serum microRNA as biological markers for the prediction of the biological behavior and prognosis of breast cancer. Methods Real - time quantitative RT - PCR was applied to analyze the expression of target microRNAs in the serum of 165 untreated breast cancer patients and 120 healthy control subjects from March 2011 to October 2011 in Tianjin Cancer Hospital, and t -test was used to compare the differences of serum target microRNAs be- tween breast cancer patients and normal controls. The relationship between serum miRNA expression and the clinical and patholog- ical profiles of breast cancer was analyzed by using Mann - Whitney test and Kruskal - Wallis test. Results 4 microRNAs （miR -10b, miR -100, miR -155 and miR -206） were obtained through early microRNA microarrays which were used to an- alyze the miRNA expression profiles of breast tumor tissue and the corresponding adjacent normal tissue. Compared with the normal control group, serum expression of miR- 100 and miR- 206 was significantly down- regulated in breast cancer patients, while miR -155 expression was significantly up -regulated in breast cancer patients （P 〈 0.05 ） and no statistically significant differ- ence was found in serum levels of miR - 10b （ P 〉 0. 05 ） . The content of miR - 10b between lymph node metastasis and no lymph node metastasis breast cancer, the content of miR - 155 among different clinical stage, between different F53 and Ki - 67 mutation status, and the content of miR -206 among different molecular type and estrogen receptor （ER） status were significantly different （ P 〈 0.05） . Conclusion Serum microRNAs are novel biomarkers for breast cancer, and miR - lob and miR - 206 can be used for the early prediction of lymph node metastasis and the presence of estrogen receptor in breast cancer patients, re- spectively, and miRNA - 155 can be used to determine the propensity for tumor malignancy and to predict the clinical stage.
出处
《中国全科医学》
CAS
CSCD
北大核心
2013年第15期1736-1739,共4页
Chinese General Practice
基金
国家自然科学基金资助项目(22HB548)
天津市科技支撑重大资助项目(09ZCZDSF04000)
